Dr Pascal Hickey (BPharm, PhD)
Chief Executive Officer
Dr Sara Prickett (BSc, PhD)
Chief Scientific Officer
Sara Prickett has over 15 years’ research experience in cellular immunology and was responsible for the preclinical development of Aravax's peanut allergy therapy. Prior to Aravax, Dr Prickett held senior research posts within Alfred Health and Monash University.
Dr Prickett received her Bachelor of Science from Sheffield University and PhD from Imperial College, London.
Professor Robyn O'Hehir (PhD, FAHMS, FRACP, FRCP, FRCPath, AO)
Chief Medical Advisor
Robyn O’Hehir has over 25 years’ research experience as an international allergy clinician and scientist. She is Professor/Director of the Department of Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University where her research team identified the critical components of the peanut allergy therapy being developed by Aravax.
Professor O’Hehir received her medical degree from Monash University, Australia, her PhD from the University of London, U.K. and her Specialist Physician Fellowships from both Australia and U.K.
Judy Bingham (BPharm, MHA)
Director Clinical Operations
Judy Bingham has over 20 years' clinical development and regulatory strategy experience in the Australian and international pharmaceutical and biotechnology industries, including 10 years as Senior Director, Consulting Services at Kendle International (now Syneos Health) and pharmaceutical companies Faulding (now Pfizer) and CSL.
Judy has a Bachelor of Pharmacy from Victorian College of Pharmacy (Monash University), is a Fellow of the Society of Hospital Pharmacists of Australia and has a Masters in Health Science from Latrobe University. She is a Graduate of the Australian Institute of Company Directors, formerly a Director of ARCS, and is a Director of Easington Pty Ltd.
Dr Paul Laidler (BPharm, PhD)
Director Product Development
Paul Laidler has over 20 years' pharmaceutical development experience having held a number of roles within large Pharmaceutical companies including Zeneca/AstraZeneca and a number of rapidly developing biotechnology companies including PowderJect Technologies, Chiron Vaccines, PowderMed and most recently Circassia Pharmaceuticals. Prior to setting up as an independent consultant, Dr Laidler was Vice President of Pharmaceutical Sciences at Circassia Pharmaceuticals where he had responsibility for all aspects of the chemistry, manufacturing, controls (CMC) and supply of a number of multipeptide products.
Dr Laidler received both his Bachelor of Pharmacy and Ph.D. degrees from King’s College London.